Liver Disease Clinical Trials

138 clinical trials for Liver Disease across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Evaluation of Patients With Liver Disease — RECRUITING
• Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians — RECRUITING
• Online Prehabilitation for Patients Awaiting Liver Transplantation — RECRUITING · NA
• A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GSK4532990 FOR STEATOHEPATITIS IN ADULTS WITH ALCOHOL RELATED LIVER DISEASE (ALD) — RECRUITING · PHASE2
• Safety and Efficacy of Fecal Microbiota Transplantation — RECRUITING · NA
• EFFECTS OF NNC0194-0499 ALONE AND IN COMBINATION WITH SEMAGLUTIDE, OF SEMAGLUTIDE ALONE, AND OF CAGRILINTIDE ALONE AND IN COMBINATION WITH SEMAGLUTIDE ON LIVER DAMAGE AND ALCOHOL USE IN PEOPLE WITH ALCOHOL-RELATED LIVER DISEASE — RECRUITING
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FAZIRSIRAN IN THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY-ASSOCIATED LIVER DISEASE WITH METAVIR STAGE F1 FIBROSIS — RECRUITING · PHASE3
• Copenhagen Comorbidity in HIV Infection Study — ACTIVE_NOT_RECRUITING
• Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease — COMPLETED
• A DOSE-FINDING, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TREATMENT WITH EFIMOSFERMIN ALFA IN ADULT PARTICIPANTS WITH ALCOHOL-RELATED LIVER DISEASE (ALD) (ALLSTAR) — NOT_YET_RECRUITING · PHASE2
• Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) — COMPLETED · PHASE2
• A PHASE 1/2, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION, DOSE EXPANSION, AND SINGLE REPEAT DOSE STUDY OF TSRA-196 IN ADULTS WITH THE PIZZ GENOTYPE WHO HAVE LUNG AND/OR LIVER DISEASE ASSOCIATED WITH SEVERE ALPHA-1 ANTITRYPSIN DEFICIENCY — NOT_YET_RECRUITING · PHASE1
• Impact of Delta Model of End Stage Liver Disease (MELD) in High MELD Liver Transplant Recipients — COMPLETED
• Donor and Recipient Mismatch in Liver Transplantation — COMPLETED
• Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices — NOT_YET_RECRUITING
• Quantitative Evaluation of the Progression of Liver Disease, Using ShearWaveTM — COMPLETED
• Observational Study for the Characterisation of Patients Affected by Any Type of Diabetes and Endocrine Disorders — NOT_YET_RECRUITING
• Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease — ACTIVE_NOT_RECRUITING
• Use of Indocyanine Green Cholangiography and Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy — COMPLETED · PHASE3
• Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk — NOT_YET_RECRUITING · NA
• Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction — TERMINATED · PHASE1
• Randomised Prospective Study of CUSA Versus Radiofrequency Ablation Technique in Liver Resections — COMPLETED · NA
• A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems — COMPLETED · PHASE1
• Biomarkers for the Detection of Heavy Alcohol Use in Patients With and Without Liver Disease — OTHER · NA
• MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease — COMPLETED
• A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF NST-6179 IN ADULT SUBJECTS WITH INTESTINAL FAILURE-ASSOCIATED LIVER DISEASE (IFALD) — COMPLETED · PHASE2
• Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment. — COMPLETED
• Transient Elastography in the Determination of Advanced Fibrosis in Alcoholic Liver Disease. — COMPLETED · NA
• Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101) — COMPLETED
• Estimation of Minimum Efficacy Daily Dose of Jarlsberg Cheese — COMPLETED · NA
• Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus — COMPLETED · PHASE4
• deLIVER: Direct Acting Antiviral Effects on the Liver — COMPLETED · PHASE4
• NAFLD Pediatric Database 2 — COMPLETED
• Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2 — COMPLETED
• The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor. — COMPLETED · PHASE1
• Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon — COMPLETED · PHASE2
• Screening of Patients Admitted to a Local Hospital With Pocket-sized Ultrasound — COMPLETED
• Influence of Routinely Adding Ultrasound Screening in Medical Department — COMPLETED · NA
• Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV) — COMPLETED · PHASE2
• Inflammation and Obesity-associated Disease — OTHER
• Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG) — COMPLETED · PHASE3
• Evaluation of the Involvement of the Intestinal Microbiota and Choline Deficiency in the Severity of Chronic Liver Disease Explored by Analyzing Collection of Biological Samples (MICRONACH) — COMPLETED
• Heritability of Fatty Liver as Measured by MRI: a Cross Sectional Study of Twins and Family Members — OTHER
• Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients — OTHER · PHASE2
• Magnetic Resonance Elastography in Infants — TERMINATED · NA
• Controlled Attenuation Parameter (CAP) in Liver Allografts — COMPLETED
• Patient-Centered Care and Asian Americans — COMPLETED · NA
• A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency — COMPLETED · PHASE1
• Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease — COMPLETED · PHASE4
• Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients — COMPLETED · PHASE1

Refine this search